Generalized verrucosis in a patient with GATA2 deficiency

Generalized verrucosis is a characteristic of several genetic and immunodeficiency disorders including epidermodysplasia verruciformis; warts, hypogammaglobulinaemia, infections and myelokathexis (WHIM) syndrome; warts, immunodeficiency, lymphoedema and anogenital dysplasia (WILD) syndrome; severe combined immune deficiency and HIV, among others. In recent years, it has been consistently recognized in patients with GATA2 deficiency, a novel immunodeficiency syndrome characterized by monocytopenia, B‐cell and natural killer‐cell lymphopenia, and a tendency to develop myeloid leukaemias and disseminated mycobacterial, human papillomavirus (HPV) and opportunistic fungal infections. Mutations in GATA2 cause haploinsufficiency and track in families as an autosomal dominant immunodeficiency. GATA2 is a transcription factor involved in early haematopoietic differentiation and lymphatic and vascular development. We describe a case of generalized verrucosis with HPV type 57 presenting in a young man with GATA2 deficiency. GATA2 deficiency is a novel dominant immunodeficiency that is often recognized later in life and should be considered in the differential diagnosis of patients with generalized verrucosis.

[1]  J. Orange,et al.  GATA2 deficiency: a protean disorder of hematopoiesis, lymphatics, and immunity. , 2014, Blood.

[2]  J. Orange,et al.  Mutations in GATA2 cause human NK cell deficiency with specific loss of the CD56(bright) subset. , 2013, Blood.

[3]  Steven M Holland,et al.  Warts and all: human papillomavirus in primary immunodeficiencies. , 2012, The Journal of allergy and clinical immunology.

[4]  J. Rosenfeld,et al.  Loss-of-function germline GATA2 mutations in patients with MDS/AML or MonoMAC syndrome and primary lymphedema reveal a key role for GATA2 in the lymphatic vasculature. , 2012, Blood.

[5]  S. Tyring,et al.  Generalized verrucosis: a review of the associated diseases, evaluation, and treatments. , 2012, Journal of the American Academy of Dermatology.

[6]  Sahar Mansour,et al.  Mutations in GATA2 cause primary lymphedema associated with a predisposition to acute myeloid leukemia (Emberger syndrome) , 2011, Nature Genetics.

[7]  S. Holland,et al.  Successful allogeneic hematopoietic stem cell transplantation for GATA2 deficiency. , 2011, Blood.

[8]  Smita Y. Patel,et al.  Mutations in GATA2 are associated with the autosomal dominant and sporadic monocytopenia and mycobacterial infection (MonoMAC) syndrome. , 2011, Blood.

[9]  Anna L. Brown,et al.  Heritable GATA2 Mutations Associated with Familial Myelodysplastic Syndrome and Acute Myeloid Leukemia , 2011, Nature Genetics.

[10]  N. McGovern,et al.  The human syndrome of dendritic cell, monocyte, B and NK lymphoid deficiency , 2011, The Journal of experimental medicine.

[11]  B. Steinberg,et al.  Recurrent respiratory papillomatosis: a complex defect in immune responsiveness to human papillomavirus‐6 and ‐11 , 2010, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[12]  D. Murrell,et al.  Recalcitrant cutaneous warts treated with recombinant quadrivalent human papillomavirus vaccine (types 6, 11, 16, and 18) in a developmentally delayed, 31-year-old white man. , 2010, Archives of dermatology.

[13]  Adeline R. Whitney,et al.  Autosomal dominant and sporadic monocytopenia with susceptibility to mycobacteria, fungi, papillomaviruses, and myelodysplasia. , 2010, Blood.

[14]  Tariq Enver,et al.  GATA-2 regulates granulocyte-macrophage progenitor cell function. , 2008, Blood.

[15]  P. Altmeyer,et al.  A human papillomavirus-associated disease with disseminated warts, depressed cell-mediated immunity, primary lymphedema, and anogenital dysplasia: WILD syndrome. , 2008, Archives of dermatology.

[16]  A. Coutinho,et al.  Immunity to Microbes: Lessons from Primary Immunodeficiencies , 2007, Infection and Immunity.

[17]  J. McGregor,et al.  Imiquimod cream 5% for recalcitrant cutaneous warts in immunosuppressed individuals , 2005, The British journal of dermatology.

[18]  S. Tyring,et al.  Therapy of cutaneous human Papillomavirus infections , 2004, Dermatologic therapy.

[19]  Elaine Dzierzak,et al.  GATA-2 Plays Two Functionally Distinct Roles during the Ontogeny of Hematopoietic Stem Cells , 2004, The Journal of experimental medicine.

[20]  I. Arany,et al.  All-trans retinoic acid (ATRA) suppresses transcription of human papillomavirus type 16 (HPV16) in a dose-dependent manner. , 2004, Anticancer research.

[21]  G. Plum,et al.  Immunological defense mechanisms in tuberculosis and MAC-infection. , 1999, Diagnostic microbiology and infectious disease.

[22]  S H Chew,et al.  Phylogenetic analysis of the human papillomavirus type 2 (HPV-2), HPV-27, and HPV-57 group, which is associated with common warts. , 1997, Virology.

[23]  S. Jabłońska,et al.  Cellular immunity in cutaneous and genital HPV infections. , 1997, Clinics in dermatology.

[24]  H. Smits,et al.  Nested PCR approach for detection and typing of epidermodysplasia verruciformis-associated human papillomavirus types in cutaneous cancers from renal transplant recipients , 1995, Journal of clinical microbiology.

[25]  S. Kondo,et al.  Effects of a novel topical immunomodulator, imiquimod, on keratinocyte cytokine gene expression. , 1994, Lymphokine and cytokine research.

[26]  D. Manias,et al.  Epidermodysplasia Verruciformis: A Case Associated With Primary Lymphatic Dysplasia, Depressed Cell-Mediated Immunity, and Bowen's Disease Containing Human Papillomavirus 16 DNA , 1987 .

[27]  S. Holland,et al.  Cutaneous manifestations of DOCK8 deficiency syndrome. , 2012, Archives of dermatology.

[28]  V. Prieto,et al.  Common Variable Immunodeficiency Syndrome Associated with Epidermodysplasia Verruciformis , 2007, American journal of clinical dermatology.